We continuously integrate innovations in machine learning, biology, and chemistry to push AI's boundaries in drug discovery.
Our AI-designed proprietary drug MDR-001, an oral small-molecule GLP-1 RA, obtained US IND approval in 19 months since program initiation, for the treatment of obesity and type 2 diabetes mellitus. The dosing of the first cohort in the Phase II study of MDR-001 has been completed.
Cooperations with biopharma in AI-enabled drug discovery with a focus on Hard-to-Drug molecular targets.
MindRank has successfully delivered an allosteric inhibitor PCC with Best-in-Class potential to a public traded biotech company.
MindRank comprises of over 40 scientists, including top biopharma experts and global AI competition winners. The team possesses rich industrial experience and success stories in drug discovery and AI-driven technological innovations.
Some of the innovations were published in scientific journals such as Nature Biomedical Engineering, Patterns (Cell Press), Advanced Science, and in reputable conferences such as ICML, IJCAI, and KDD.
MindRank was recognized as one of the "100 to Watch" in Forbes Asia's 2023 list. Its pan-European collaborative project secured funding from the Dynamic Resilience program, launched by Wellcome Leap and Temasek Trust. Additionally, its proprietary AI solution was nominated by Deep Pharma Intelligence as one of the "Top AI Breakthroughs in Biopharma from 2018 to 2020".